Ernst-Rudolf Kempe
Boehringer Ingelheim (Germany)(DE)
Publications by Year
Research Areas
Platelet Disorders and Treatments, Immunotherapy and Immune Responses, Antiplatelet Therapy and Cardiovascular Diseases, Heparin-Induced Thrombocytopenia and Thrombosis, vaccines and immunoinformatics approaches
Most-Cited Works
- → Phase I Study to the Immunotherapy of Metastatic Malignant Melanoma by a Cancer Vaccine Consisting of Autologous Cancer Cells Transfected with the Human IL-2 Gene. University of Vienna, Austria(1996)39 cited
- → Genotypic variations in ethanol effect on striatal and hippocampal transmitter interactions(1985)20 cited
- Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.(1991)
- → Failure of the platelet-activating-factor antagonist WEB 2086 BS for treatment of chronic autoimmune thrombocytopenia(1990)15 cited
- → Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene(1997)14 cited
- → Effect of intravenous or inhalative web 2086 on ex vivo platelet activating factor induced platelet aggregation in man(1988)10 cited
- → PAF-acether-antagonist WEB 2086 for treatment of chronic idiopathic thrombocytopenia(1990)3 cited
- → Triazolam and PAF inhibition(1992)